Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
MAbs ; 6(3): 689-96, 2014.
Article in English | MEDLINE | ID: mdl-24572100

ABSTRACT

The neonatal Fc receptor (FcRn) plays an important and well-known role in antibody recycling in endothelial and hematopoietic cells and thus it influences the systemic pharmacokinetics (PK) of immunoglobulin G (IgG). However, considerably less is known about FcRn's role in the metabolism of IgG within individual tissues after intravenous administration. To elucidate the organ distribution and gain insight into the metabolism of humanized IgG1 antibodies with different binding affinities FcRn, comparative biodistribution studies in normal CD-1 mice were conducted. Here, we generated variants of herpes simplex virus glycoprotein D-specific antibody (humanized anti-gD) with increased and decreased FcRn binding affinity by genetic engineering without affecting antigen specificity. These antibodies were expressed in Chinese hamster ovary cell lines, purified and paired radiolabeled with iodine-125 and indium-111. Equal amounts of I-125-labeled and In-111-labeled antibodies were mixed and intravenously administered into mice at 5 mg/kg. This approach allowed us to measure both the real-time IgG uptake (I-125) and cumulative uptake of IgG and catabolites (In-111) in individual tissues up to 1 week post-injection. The PK and distribution of the wild-type IgG and the variant with enhanced binding for FcRn were largely similar to each other, but vastly different for the rapidly cleared low-FcRn-binding variant. Uptake in individual tissues varied across time, FcRn binding affinity, and radiolabeling method. The liver and spleen emerged as the most concentrated sites of IgG catabolism in the absence of FcRn protection. These data provide an increased understanding of FcRn's role in antibody PK and catabolism at the tissue level.


Subject(s)
Antibodies, Monoclonal, Humanized/pharmacokinetics , Receptors, Fc/metabolism , Animals , Animals, Newborn , Antibodies, Monoclonal, Humanized/administration & dosage , Antibodies, Monoclonal, Humanized/genetics , CHO Cells , Cricetinae , Cricetulus , Female , Genetic Variation , Humans , Immunoglobulin G/administration & dosage , Immunoglobulin G/genetics , Immunoglobulin G/metabolism , Indium Radioisotopes/administration & dosage , Indium Radioisotopes/pharmacokinetics , Iodine Radioisotopes/administration & dosage , Iodine Radioisotopes/pharmacokinetics , Mice , Proteolysis , Receptors, Fc/genetics , Tissue Distribution
2.
J Med Chem ; 56(23): 9418-26, 2013 Dec 12.
Article in English | MEDLINE | ID: mdl-24131491

ABSTRACT

A known limitation of iodine radionuclides for labeling and biological tracking of receptor targeted proteins is the tendency of iodotyrosine to rapidly diffuse from cells following endocytosis and lysosomal degradation. In contrast, radiometal-chelate complexes such as indium-111-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (In-111-DOTA) accumulate within target cells due to the residualizing properties of the polar, charged metal-chelate-amino acid adduct. Iodine radionuclides boast a diversity of nuclear properties and chemical means for incorporation, prompting efforts to covalently link radioiodine with residualizing molecules. Herein, we describe the Ugi-assisted synthesis of [I-125]HIP-DOTA, a 4-hydroxy-3-iodophenyl (HIP) derivative of DOTA, and demonstration of its residualizing properties in a murine xenograft model. Overall, this study displays the power of multicomponent synthesis to yield a versatile radioactive probe for antibodies across multiple therapeutic areas with potential applications in both preclinical biodistribution studies and clinical radioimmunotherapies.


Subject(s)
Antibodies, Monoclonal, Murine-Derived/metabolism , Dipeptides/chemical synthesis , Heterocyclic Compounds, 1-Ring/chemical synthesis , Immunoconjugates/chemistry , Succinimides/chemical synthesis , Animals , Antibodies, Monoclonal, Murine-Derived/chemistry , Antibodies, Monoclonal, Murine-Derived/therapeutic use , Coordination Complexes/metabolism , Dipeptides/metabolism , Heterocyclic Compounds, 1-Ring/metabolism , Immunoconjugates/metabolism , Indium Radioisotopes , Mice , Radioimmunotherapy , Succinimides/metabolism , Xenograft Model Antitumor Assays
SELECTION OF CITATIONS
SEARCH DETAIL
...